CHU Toulouse
- Address
- 1 Avenue Irene Joliot Curie, Toulouse, France
CHU Toulouse - Advanced Oncology and Transplantation Research Center
CHU Toulouse is a leading academic medical center conducting innovative clinical research in multiple oncology disciplines. The center demonstrates particular expertise in advanced cancer therapeutics and hematopoietic stem cell transplantation, focusing on improving outcomes for patients with complex hematological and solid tumor malignancies.
- Prostate cancer with metastatic disease utilizing combination radiotherapy and hormonal therapy strategies
- Haploidentical hematopoietic stem cell transplantation for hematological malignancies
- Novel androgen deprivation therapy combinations in hormone-naïve prostate cancer
- Optimization of post-transplant immunosuppression protocols with cyclophosphamide
The research portfolio at CHU Toulouse encompasses phase III randomized trials evaluating both targeted cancer therapies and transplantation protocols. Their work in prostate cancer focuses on patients with pelvic lymph node metastases, investigating the addition of darolutamide to standard androgen deprivation therapy and radiation. In the transplantation field, the center is pioneering dose-reduction strategies for post-transplant cyclophosphamide to improve graft-versus-host disease-free, relapse-free survival outcomes in patients undergoing haploidentical stem cell transplantation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1ARTIC1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU Toulouse
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Darolutamide Addition to Androgen Deprivation and Radiation Therapy in Hormone-Naïve Prostate Cancer with Pelvic Lymph Node Metastases | ARTIC | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 1 | Unknown | — | — |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.